EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration

Jiemei Shi, Huan Xu, Hongmei Zhao, Jiajie Zhao, Lihui Chen, Ping Xu, Dan Jia, Chunhui Jiang

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.4.47 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Jiemei Shi and 7 co-authors. Institution: Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Recombinant Fusion Proteins, Genetic Therapy, Receptors, Vascular Endothelial Growth Factor, Dependovirus. 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

To evaluate the safety and efficacy of a novel gene therapy vector, covalently closed-end double-stranded adeno-associated virus-aflibercept-Fc-YTE (cceAAV-aflibercept-Fc-YTE; clinical trial name F-CRG-B191), designed for sustained anti-vascular endothelial growth factor (VEGF) expression in the treatment of neovascular age-related macular degeneration (nAMD).

Methods

We developed cceAAV-aflibercept-Fc-YTE. The therapeutic efficacy of cceAAV-aflibercept-Fc-YTE was evaluated in both mice and non-human primate (NHP) models with laser-induced choroidal neovascularization (CNV). The incidence of grade IV CNV lesions was quantified. A first-in-human administration of F-CRG-B191 was conducted to assess anatomical and functional outcomes, as well as safety. Immune responses and retinal toxicity were monitored in NHPs and the patient post-injection.

Results

Compared to conventional AAV vectors expressing aflibercept, cceAAV-aflibercept-Fc-YTE significantly reduced the incidence of grade IV CNV lesions in both mice and NHP models. In the human subject, F-CRG-B191 administration led to a sustained reduction in CNV area and improvement in visual acuity. No significant immune response or retinal toxicity was observed in either preclinical models or the treated patient. Conclusions: cceAAV-aflibercept-Fc-YTE (F-CRG-B191) is a promising gene therapy candidate for nAMD, demonstrating potent anti-VEGF efficacy, durable therapeutic effects, and favorable safety profiles in both preclinical and early clinical settings.

Subjects

MeSH terms (MEDLINE)

Recombinant Fusion ProteinsGenetic TherapyReceptors, Vascular Endothelial Growth FactorDependovirusChoroidal NeovascularizationMacular DegenerationWet Macular DegenerationAnimalsMiceHumansGene Therapy AgentsDisease Models, AnimalVascular Endothelial Growth Factor AFemaleGenetic VectorsMaleTreatment OutcomeVisual AcuityMacaca fascicularis

Substances

Recombinant Fusion ProteinsafliberceptReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Authors and institutions

  • Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China.
  • Shanghai Correge Pharmaceutical Technology Co., Ltd., Shanghai, China.

Cite

APA

Shi, J., Xu, H., Zhao, H., Zhao, J., Chen, L., Xu, P., Jia, D., & Jiang, C. (2026). Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.4.47

Vancouver

Shi J, Xu H, Zhao H, Zhao J, Chen L, Xu P, et al. Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.4.47

BibTeX
@article{Shi2026,
  author = {Shi, Jiemei and Xu, Huan and Zhao, Hongmei and Zhao, Jiajie and Chen, Lihui and Xu, Ping and Jia, Dan and Jiang, Chunhui},
  title = {Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.4.47}
}
Start for free →